Author

R. Guenter

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Chen· 3 shared A. M. Carter· 2 shared A. W. Beck· 1 shared B. Herring· 1 shared B. Ren· 1 shared C. Graham· 1 shared C. Tan· 1 shared D. Hurst· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

H. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors

A. M. Carter, N. Kumar, B. Herring, C. Tan, R. Guenter, R. Telange, W. Howse, F. Viol, C. Graham, T. R. McCaw, h. Bickerton, F. Gillardon, E. A. Woltering, J. Totenhagen, R. Banerjee, , J. Bibb

This paper develops a mouse model of PanNETs driven by Cdk5 and shows its relevance to human tumors, supporting Cdk5 as a therapeutic target.

bioRxiv · May 25, 2021Cancer Biology

LPA/PKD-1 signaling promotes development of arteriolar niche that supports self-renewal of breast cancer stem cells and stemness

Y. Jiang, Y. Guo, J. Hao, R. Guenter, J. Lathia, A. W. Beck, R. Hattaway, D. Hurst, Q. J. Wang, Y. Liu, Q. Cao, H. Krontiras, H. Chen, R. L. Silverstein, B. Ren

bioRxiv · Oct 22, 2020Cancer Biology

Novel anti-somatostatin receptor 2 antibody-drug conjugate for neuroendocrine cancer therapy

Y. Si, S. Kim, R. Guenter, J. Ou, Y. Lu, K. Chen, J. Zhang, J. Whitt, A. M. Carter, J. A. Bibb, J. M. Markert, R. Jaskula-Sztul, L. Zhou, H. Chen, X. Liu

This study develops an anti-somatostatin receptor 2 antibody-drug conjugate (ADC) that effectively targets and kills neuroendocrine tumors with minimal toxicity.

bioRxiv · Nov 18, 2019 · PreprintBioengineering